Patents Assigned to ANTECIP BIOVENTURES II LLC
  • Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
    Patent number: 10413561
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: September 17, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Neridronic acid for treating complex regional pain syndrome
    Patent number: 10350227
    Abstract: Neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: July 16, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10335424
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: July 2, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10265332
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as osteoarthritis.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: April 23, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 10251879
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: April 9, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10238672
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 26, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10195141
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: February 5, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10195223
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: February 5, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Methods for the safe administration of imidazole or imidazolium compounds
    Patent number: 10173986
    Abstract: Methods for the safe administration of imidazole or imidazolium compounds such as zoledronic acid, and conditions that may be treated by these methods, are described herein.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: January 8, 2019
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10137139
    Abstract: Osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: November 27, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Neridronic acid for treating complex regional pain syndrome
    Patent number: 10117880
    Abstract: Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid form or a salt form can be used to treat or alleviate pain or related conditions, such as allodynia associated with complex regional pain syndrome.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: November 6, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10111894
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 30, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Dosage forms for oral administration of zoledronic acid or related compounds
    Patent number: 10111837
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid in an acid or a salt form, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: October 30, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 10111891
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: October 30, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10105361
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: October 23, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
    Patent number: 10105327
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 23, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10092560
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 9, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Osteoclast inhibitors such as zoledronic acid for low back pain treatment
    Patent number: 10092581
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as Modic changes type 1.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: October 9, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Jaro I. Karppinen
  • Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
    Patent number: 10092561
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 9, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10080727
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: September 25, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau